Pfizer Inc
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer Lorbrena / Lorviqua (lorlatinib by Year
Lorbrena / Lorviqua (lorlatinib — ALK+ NSCLC) — U.S. revenues ($M) ($M)
Pfizer Lorbrena / Lorviqua (lorlatinib: $407M in FY2025, up 33.0% from a year earlier.
Where the FY2025 figure comes from
“|| Lorbrena | 1,023 | 731 | 40% | 40% | 407 | 306 | 33% | 616 | 424 | 45% | 44%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Lorbrena / Lorviqua (lorlatinib — ALK+ NSCLC) — U.S. revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 407 | +33.0% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 306 | +36.6% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 224 | +474.4% | Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 39 | -2.5% | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
| FY2021 | Dec 31, 2021 | 40 | +8.1% | Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗ |
| FY2020 | Dec 31, 2020 | 37 | +42.3% | Form 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗ |
| FY2019 | Dec 31, 2019 | 26 | – | Form 8-K (Earnings / Guidance Release) (pfe-12312020xex99.htm, filed 2021-02-02) ↗ |
Breakdown
What makes up lorbrena / Lorviqua (lorlatinib
Cite this data
StockData. (2026). Pfizer Lorbrena / Lorviqua (lorlatinib ($M), annual FY2019–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/lorbrena-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.